BIOMARK CLOSES THE PRIVATE PLACEMENT OFFERING
April 16th, 2019 – Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of April 9th, 2019, it has closed the non-brokered private placement for gross proceeds of $200,000.00 wherein BioMark issued 2,000,000 units at a price […]
BIOMARK ANNOUNCES THE PRIVATE PLACEMENT
Vancouver, British Columbia – (April 9th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 2,000,000 Units at a price of $0.10 to raise gross proceeds of up to $200,000. Each Unit is composed […]
BIOMARK’S ABSTRACT ACCEPTED FOR 2019 ASCO ONLINE PUBLICATION
Vancouver, British Columbia – (April 3, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) under Dr. Andrew Maksymiuk was accepted for online publication. The abstract was titled “Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 […]
Cancer risk in families
If you have family members with cancer, you may wonder if you are at risk of developing it too (if it “runs in the family”). Sometimes a gene mutation that can cause cancer is passed on to you by your parents (inherited). Cancers caused by inherited gene mutations are called inherited cancers. And sometimes cancer […]
About Glioblastoma (GBM)
Overview Tumour Group: Gliomas WHO Grade: Grade IV Prevalence/Incidence: The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours. GBMs increase in frequency with age, and affect […]
Lung Cancer Screening in Real World Has High False-Positive Rate
By Kelly YoungEdited by: David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD A pair of studies in JAMA Internal Medicine illustrate the difficulties of implementing lung cancer screening. In the first, eight Veterans Health Administration medical centers identified and screened patients using low-dose computed tomography (LDCT). Over 2100 patients who were eligible for screening based […]
Opportunities and challenges for lung cancer screening in China
Chuanli Ren, Chongxu Han Abstract China accounts for nearly half of the incidence and mortality of lung cancer in the world. Furthermore, trends in lung cancer in China are increasing younger in age and the situation is deteriorating. As a whole although screening for early lung cancer may cause a small fraction of overdiagnosis and anxiety of […]
BioMark Contributes Additional Scientific Publication
Vancouver, British Columbia – (March 14th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed journal Future Science OA. […]
BioMark Announces New Patent Granted in China
Vancouver, British Columbia – (March 12, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been granted in China on February 15, 2019. Rashid Ahmed, President and CEO, says, “Granting of this patent expands […]